MesoPher Cell Therapy Increases 2-Year RFS Rate in Resected Pancreatic Cancer by 50%; Amphera Announces Publication of Phase II Results in Journal of Clinical Oncology and Orphan Designation Granted by FDA & EMA

 

New Data Show Almirall´s EBGLYSS® (Lebrikizumab) Provided Sustained Disease Control for up to Three Years in More Than 80% of Adults and Adolescents With Moderate-to-severe Atopic Dermatitis

 

Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress

 

CleanNA introduces CE-IVD compliant CleanNGS Dx

 

The Things Industries Launches Next-Generation Managed LoRaWAN® Gateway

 

LEO Pharma Unveils Most Extensive EADV Program To Date with 5 Late Breaking Abstracts and 23 Posters Sharing Clinical and Real-World Data

 

Semtech and Traxmate Enable Precision IoT Asset Tracking

 

"5 Million Views in 10 Days!" - Viral Sensation Mikko Rautiainen Reflects on His Record-Breaking Performance on Holland’s Got Talent, by Filmikko

 

EADV 2024 Late Breaking News Sessions: New Galderma Data Demonstrating Nemolizumab’s Long-term Efficacy and Safety in Atopic Dermatitis and Durability in Prurigo Nodularis to Be Shared During Three Oral Presentations

 

The UK Government and Dutch Development Bank FMO Commit $55 Million to BTG Pactual TIG’s Latin American Reforestation Strategy